Company intelligence / Profile preview

Sewon Cellontech Co., Ltd.

Seoul, Seoul, South Koreasc-plant.com ↗

Ownership: Private
Employees: ~48
Development stage: Commercial

Overview

The company has developed and commercialized multiple cell therapy products and medical devices, including ChondronTM for cartilage repair and RMS OssronTM for bone formation. Their products have received regulatory approvals in Korea and internationally.

Therapeutic areas: DermatologyRheumatology
Modalities: Cell therapyCollagen-based productsTissue engineering
Industry: Biotech

Drug pipeline

3 assets

autologous cultured chondrocytes (Sewon Cellontech Co., Ltd.)

Approved

2 more assets in the full pipeline.

Request access →

Partnerships

LinkoCare Life Sciences (Sweden)

Beyond the preview

Go deeper on Sewon Cellontech Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sewon Cellontech Co., Ltd..

Explore the full profile